Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY), and the FY2025 annual result was $1.3 million, changed N/A from the prior year.
• Other Non-Current Liabilities steadied at $1.3 million in Q1 2026 per VVOS's latest filing, from $1.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.2 million in Q2 2023 and troughed at $101000.0 in Q1 2022.
• A 4-year average of $1.2 million and a median of $1.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 1219.8% in 2023 and fell as far as 1219.8% in 2023.
• A 4-year view of Other Non-Current Liabilities shows it stood at $101000.0 in 2022, then soared by 494.06% to $600000.0 in 2023, then surged by 116.67% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Business Quant data shows VVOS's Other Non-Current Liabilities at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.